Skip to main content

Table 2 Drug-related adverse events

From: Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study

Adverse events

ICIs maintenance

ICIs + Pem maintenance

All

(n = 24)

Grade 1–2

(n = 18)

Grade 3–4

(n = 6)

All

(n = 76)

Grade 1–2

(n = 61)

Grade 3–4

(n = 15)

Hematologic toxicity

7

6

1

19

10

9

Pneumonia

3

2

1

12

7

5

Thyroid/hyperglycemia

2

2

0

6

6

0

Elevated LFTs

2

1

1

2

2

0

Diarrhea or colitis

2

1

1

1

1

0

Fatigue

2

2

0

18

18

0

Skin/rash

5

3

2

3

2

1

Peripheral edema

1

1

0

5

5

0

Decreased appetite

0

0

0

6

6

0

RCCEP

0

0

0

4

4

0

  1. ICIs Immune checkpoint inhibitors, Pem Pemetrexed, LFTs Liver function tests, RCCEP Reactive cutaneous capillary endothelial proliferation
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us